- Home
- AISP vs PBYI Comparison
AISP vs PBYI Comparison
Compare AISP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AISP
- PBYI
- Stock Information
- Founded
- AISP 2006
- PBYI 2010
- Country
- AISP United States
- PBYI United States
- Employees
- AISP N/A
- PBYI N/A
- Industry
- AISP Blank Checks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- AISP Finance
- PBYI Health Care
- Exchange
- AISP Nasdaq
- PBYI Nasdaq
- Market Cap
- AISP 166.9M
- PBYI 171.7M
- IPO Year
- AISP N/A
- PBYI N/A
- Fundamental
- Price
- AISP $4.96
- PBYI $3.07
- Analyst Decision
- AISP Strong Buy
- PBYI Strong Buy
- Analyst Count
- AISP 1
- PBYI 1
- Target Price
- AISP $6.00
- PBYI $7.00
- AVG Volume (30 Days)
- AISP 1.2M
- PBYI 319.7K
- Earning Date
- AISP 08-13-2025
- PBYI 08-07-2025
- Dividend Yield
- AISP N/A
- PBYI N/A
- EPS Growth
- AISP N/A
- PBYI 143.51
- EPS
- AISP N/A
- PBYI 0.77
- Revenue
- AISP $17,978,226.00
- PBYI $232,709,000.00
- Revenue This Year
- AISP $34.52
- PBYI N/A
- Revenue Next Year
- AISP $59.54
- PBYI N/A
- P/E Ratio
- AISP N/A
- PBYI $3.97
- Revenue Growth
- AISP N/A
- PBYI 2.68
- 52 Week Low
- AISP $1.90
- PBYI $2.23
- 52 Week High
- AISP $7.66
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- AISP 41.19
- PBYI 33.07
- Support Level
- AISP $5.05
- PBYI $3.23
- Resistance Level
- AISP $5.34
- PBYI $3.41
- Average True Range (ATR)
- AISP 0.39
- PBYI 0.13
- MACD
- AISP -0.09
- PBYI -0.04
- Stochastic Oscillator
- AISP 10.67
- PBYI 6.67
About AISP Airship AI Holdings Inc.
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.